Axovant Sciences Acquires Drug from GlaxoSmithKline Amid Political Claims
What happened
Axovant Sciences acquired the drug intepirdine from GlaxoSmithKline for $5 million. Separately, a campaign ad from Amy Acton claimed that Vivek Ramaswamy pushed an Alzheimer's drug that he knew was ineffective and that he made hundreds of millions of dollars scamming people. PolitiFact also reported on Mike Rogers' claims that Abdul El-Sayed was not a doctor, a claim which was fact-checked against state laws and medical definitions.
From newsroomamerica.com
Why it matters
The acquisition links Axovant Sciences to GlaxoSmithKline's drug portfolio. The political claims made by Amy Acton regarding Vivek Ramaswamy and the drug could impact investor perception of Axovant Sciences and its related assets.
From newsroomamerica.com
Who's involved
- Axovant SciencesAcquired the drug intepirdine from GlaxoSmithKline
- GlaxoSmithKlineSold the drug intepirdine to Axovant Sciences
- Amy ActonUsed a campaign ad to target Vivek Ramaswamy
- Vivek RamaswamyTargeted by Amy Acton's campaign ad regarding drug sales
- Mike RogersMade claims about Abdul El-Sayed's medical credentials
- Abdul El-SayedSubject of Mike Rogers' claims regarding medical credentials
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Axovant SciencesSpeculative
The drug's failure and potential stock price drop might materially harm its financial standing via market price.
Keep exploring
The entities involved
-
Axovant Sciences
clinical-stage biopharmaceutical company
Nothing else this week.
-
GlaxoSmithKline
company in Tokyo, Japan
Nothing else this week.
-
Amy Acton
American physician (born 1966)
-
Mike Rogers
American politician (born 1963)